Valid Medical Discoveries Enabled by New Approach Methodologies (NAMs): Focus on AI-Driven Discovery, In Silico Modeling, Organ-on-a-Chip, and Advanced Computational Methods

- New Approach Methodologies (NAMs) encompass AI-driven discovery, in silico modeling, organ-on-a-chip (OoC), and high-throughput omics technologies.
- AI/ML has enabled de novo drug design, drug repurposing, and predictive toxicology, with validated candidates advancing to clinical trials.
- In silico models, including digital twins and PBPK, support virtual clinical trials and drug safety assessments, reducing reliance on animal testing.
- Organ-on-a-chip platforms model complex human organ physiology, enabling disease modeling and personalized medicine applications with regulatory acceptance.
- Regulatory agencies (FDA, EMA) and industry leaders increasingly adopt NAMs, driven by ethical, scientific, and economic imperatives.

Introduction

The past decade has witnessed a paradigm shift in biomedical research and drug development, driven by the emergence and maturation of New Approach Methodologies (NAMs). These methodologies leverage cutting-edge computational tools, artificial intelligence (AI), microphysiological systems, and high-throughput omics to replace or supplement traditional animal testing. The impetus for this transition is multifaceted: ethical concerns about animal welfare, the scientific limitations of animal models in predicting human responses, and the pressing need for faster, more accurate, and cost-effective drug development pipelines.

This report provides a comprehensive, structured review of medically relevant discoveries made using NAMs, focusing on four key domains: AI-driven drug discovery, in silico modeling and simulation, organ-on-a-chip technology, and high-throughput omics-based approaches. The report synthesizes peer-reviewed research from reputable journals, regulatory agency reports (FDA, EMA), and institutional sources (NIH, NC3Rs), emphasizing discoveries with experimental validation and direct clinical or regulatory impact.

AI/ML-Driven Discoveries

Drug Repurposing and De Novo Design

AI and machine learning (ML) have revolutionized drug discovery by enabling the analysis of vast chemical and biological datasets to predict drug responses and identify novel candidates. AI-driven virtual cell models integrate multimodal omics data (single-cell transcriptomics, proteomics) with advanced algorithms such as deep generative models and graph neural networks. These models provide high-precision predictions of drug responses and gene perturbations, facilitating both drug repurposing and de novo design.

A notable example is Insilico Medicine's AI platform, which designed a novel drug candidate for idiopathic pulmonary fibrosis in just 18 months, demonstrating the potential of AI to accelerate drug discovery timelines significantly. The platform screens vast chemical libraries and predicts toxicity and efficacy, reducing the need for extensive animal testing [1] [2].

Predictive Toxicology and ADMET Modeling

AI-driven models are also transforming predictive toxicology and ADMET (absorption, distribution, metabolism, excretion, toxicity) assessments. By leveraging big data and machine learning, these models identify patterns and predict toxicological profiles of compounds with high accuracy. This capability allows prioritization of safer drug candidates early in development, reducing downstream failures.

For instance, the DeepTox model, a multi-task deep neural network, won the Tox21 challenge by accurately predicting compound toxicity across multiple high-throughput assays. Such models are increasingly integrated into regulatory submissions and drug development workflows [3].

In Silico Modeling and Simulation

Virtual Clinical Trials and Digital Twins

In silico modeling enables the simulation of biological responses and drug effects in virtual environments, facilitating virtual clinical trials and the creation of digital twins. These computational representations of patients or patient subgroups are calibrated using data from organ-on-a-chip platforms and multi-omics repositories.

For example, physiologically based pharmacokinetic (PBPK) models simulate drug absorption, distribution, metabolism, and excretion, providing critical insights into drug safety and efficacy. These models support regulatory submissions and help optimize dosing regimens without animal testing [4] [5].

Physiologically Based Pharmacokinetic (PBPK) Modeling

PBPK modeling is a cornerstone of in silico approaches, enabling the prediction of drug behavior in the body. By integrating data on drug properties and human physiology, PBPK models inform drug development decisions, including dose optimization and toxicity risk assessment.

Recent advances include the integration of PBPK with organ-on-a-chip data to refine predictions, particularly for complex drug-drug interactions and disease states. This synergy enhances the accuracy of preclinical assessments and supports regulatory acceptance of NAMs [5].

Organ-on-a-Chip and Microphysiological Systems

Disease Modeling and Drug Testing

Organ-on-a-chip (OoC) platforms replicate human organ architecture and physiology in microfluidic devices, enabling dynamic studies of drug effects and disease mechanisms. These systems model complex tissue-tissue interfaces, fluid flow, and mechanical forces, providing a human-relevant alternative to animal models.

For instance, the HUMIMIC Chip2 platform integrated liver spheroids and skin models to study pharmacokinetic-pharmacodynamic (PK-PD) relationships under chemical exposure. Similarly, gut-liver OoC platforms combined with in silico modeling allow quantitative studies of drug metabolism and toxicity [5] [6].

Personalized Medicine Applications

OoC technology is advancing personalized medicine by enabling patient-specific organ chips that mimic individual genetic and physiological profiles. These platforms facilitate tailored drug testing and toxicity assessments, supporting precision medicine initiatives.

Recent regulatory milestones include the FDA's acceptance of organ-on-a-chip technologies as drug development tools, underscoring their potential to replace animal testing in preclinical safety studies [7].

High-Throughput and Omics-Based Approaches

CRISPR Screens and Single-Cell RNA Sequencing

High-throughput technologies such as CRISPR/Cas9 gene editing and single-cell RNA sequencing enable rapid identification and validation of drug targets and disease mechanisms. These methods support the discovery of novel therapeutic targets and the elucidation of molecular pathways.

For example, CRISPR screens have been used to verify AI-predicted drug targets, accelerating the discovery of new treatments for cancer and neurodegenerative diseases [3].

Multi-Omics Integration

The integration of genomics, transcriptomics, proteomics, and metabolomics data provides a holistic view of biological systems, enabling mechanistic insights into disease progression and drug action. Multi-omics approaches support biomarker discovery and pathway analysis, facilitating the development of targeted therapies.

This integrative approach is increasingly adopted in drug discovery pipelines to improve the understanding of complex diseases and enhance therapeutic strategies [3].

Regulatory and Industry Adoption

FDA Modernization Act 2.0 and Regulatory Support

The FDA Modernization Act 2.0, enacted in 2022, removed the federal mandate for animal testing in new drug applications, explicitly encouraging the use of NAMs such as in vitro and in silico models. This regulatory shift is a pivotal driver for the adoption of NAMs in preclinical safety assessments.

Regulatory agencies worldwide, including the EMA and OECD, are incorporating NAMs into risk assessment frameworks, promoting harmonization and validation of these methods [8] [6].

Industry Investments and Collaborations

Pharmaceutical and biotechnology companies are increasingly investing in NAMs to enhance drug discovery efficiency and reduce costs. For example, Roche and Johnson & Johnson have partnered with Emulate to use organ-on-a-chip platforms for toxicity prediction, while AstraZeneca is investing in organoids and computational modeling.

These investments reflect a strategic shift toward human-relevant models that improve predictivity and reduce reliance on animal testing [8].

Summary Table of Key NAM-Enabled Medical Discoveries (2014–2024)

NAM Type	Discovery/Application	Validation Status	Key References	Impact/Notes
AI/ML-Driven Discovery	De novo drug design for idiopathic pulmonary fibrosis (Insilico Medicine)	Phase II clinical trials	[1] [2]	AI-designed drug candidate in 18 months

NAM Type	Discovery/Application	Validation Status	Key References	Impact/Notes
In Silico Modeling	PBPK modeling for drug safety and PK/PD predictions	FDA-accepted for regulatory submissions	4 5	Supports virtual clinical trials
Organ-on-a-Chip	Liver and gut-liver OoC for drug toxicity and PK studies	In vitro and regulatory acceptance	5 6	FDA accepted as drug development tool
High-Throughput Omics	CRISPR screens for target validation in cancer and neurodegeneration	In vitro and in vivo validation	3	Accelerates novel target discovery
Regulatory Adoption	FDA Modernization Act 2.0 encouraging NAMs	Legislative and regulatory approval	8 6	Driving industry adoption and innovation

Conclusion

New Approach Methodologies (NAMs) have emerged as transformative tools in medical research, enabling significant discoveries across drug development, disease modeling, toxicology, and personalized medicine. AI-driven discovery, in silico modeling, organ-on-a-chip platforms, and high-throughput omics technologies collectively provide a human-relevant, efficient, and ethical alternative to traditional animal testing.

The integration of these methodologies is supported by robust regulatory frameworks and substantial industry investments, accelerating the transition toward more predictive and cost-effective drug development pipelines. As NAMs continue to evolve and validate, they will increasingly replace animal models, revolutionizing biomedical research and improving patient outcomes.

This report synthesizes the most impactful, medically relevant discoveries enabled by NAMs over the past decade, underscoring their critical role in the future of drug discovery and healthcare innovation.

9 8 10 4 5 11 12 13 7 14 6 15 16 17 18 19 20 1 21 22 23 3 24 25 26 27 28 2 29 30

---

[1] From Lab to Clinic: How Artificial Intelligence (AI) Is Reshaping Drug Discovery Timelines and Industry Outcomes - PMC
[2] AI-Driven Drug Discovery: A Comprehensive Review | ACS Omega
[3] The future of pharmaceuticals: Artificial intelligence in drug discovery and development - PMC
[4] AI-driven virtual cell models in preclinical research: technical pathways, validation

mechanisms, and clinical translation potential | npj Digital Medicine
[5] Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation | MDPI
[6] Organ-on-a-chip meets artificial intelligence in drug evaluation - PMC
[7] Beyond Animals: Revolutionizing Drug Discovery with Human-Relevant Models
[8] How new approach methodologies are reshaping drug discovery
[9] New Approach Methodologies (NAMs): The Future of Toxicology and Safety Testing
[10] Synergistic innovation in organ-on-a-chip and organoid technologies: reshaping the future of disease modeling, drug development, and precision medicine | Protein & Cell | Oxford Academic
[11] Frontiers | Modeling reproductive and pregnancy-associated tissues using organ-on-chip platforms: challenges, limitations, and the high throughput data frontier
[12] From AI-Assisted In Silico Computational Design to Preclinical In Vivo Models: A Multi-Platform Approach to Small Molecule Anti-IBD Drug Discovery | MDPI
[13] Beyond Animal Testing: The Rise of Organs-on-Chips Technology
[14] New Approach Methodologies (NAMs): Advances in preclinical safety studies | Axion Biosystems
[15] Organ-on-a-chip meets artificial intelligence in drug evaluation
[16] Organ-on-a-chip meets artificial intelligence in drug evaluation - PubMed
[17]
[18] Artificial intelligence in preclinical research: enhancing digital twins and organ-on-chip to reduce animal testing - ScienceDirect
[19] From AI-Assisted In Silico Computational Design to Preclinical In Vivo Models: A Multi-Platform Approach to Small Molecule Anti-IBD Drug Discovery - PMC
[20] Transformative Role of Artificial Intelligence in Drug Discovery and Translational Medicine: Innovations, Challenges, and Future Prospects - PMC
[21] Artificial Intelligence in Drug Discovery: Transforming the Future of Medicine - Premier Science
[22] Revolutionizing drug evaluation system with organ-on-a-chip and ...
[23] Leading artificial intelligence–driven drug discovery platforms: 2025 landscape and global outlook - ScienceDirect
[24] Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: At a glance - ScienceDirect
[25] Two New Breakthroughs Advance Neurological Disorders and Cancer Research
[26] Impact and Mechanisms of Action of BDNF on Neurological Disorders, Cancer, and Cardiovascular Diseases - PubMed
[27] NAMs (New Approach Methodologies) and Neural Stem Cells | Cells | MDPI
[28] The published role of artificial intelligence in drug discovery and development: a bibliometric and social network analysis from 1990 to 2023 - PMC
[29] Artificial Intelligence in Virtual Screening: Transforming Drug Research and Discovery—A Review | Journal of Bio-X Research
[30] How to Build the Virtual Cell with Artificial Intelligence: Priorities and Opportunities - PMC